Ofatumumab, an anti-CD20 MAb administered subcutaneously, appears to have only modest effects on serum immunoglobulins, according to an updated safety analysis from recent clinical trials (Hauser et al. Mult Scler 2022; epublished March 1, 2022). A preliminary analysis of the data was published at last year’s ECTRIMS (Wiendl et al. ECTRIMS 2021;P931) (see also ECTRIMS 2021 slide deck, NeuroSens, October 21, 2021). Read More
Latest News
Worse COVID-19 outcomes due to disability, morbidity
March 17, 2022The severe COVID-19 outcomes seen in MS patients do not appear attributable to an inherent immune dysfunction or an impaired antiviral response, but rather to MS-related disability and morbidity. That is the conclusion of the Italian MuSC-19 Study Group in its analysis of COVID-19 in MS patients (Sormani et al. Neurol Neuroimmunol Neuroinflamm 2022;9:e1105). Read More
Slide deck: COVID-19 – Epidemiology in Canada (March 11, 2022)
March 11, 2022Summary of epidemiology, cases and mortality rate; Canada and world statistics.
Can COVID vaccination cause demyelination?
March 7, 2022At the 2022 ACTRIMS Forum, three groups presented data on acute demyelinating events following COVID-19 vaccination. Read More